User:Marvin O'Neal/OspC: Difference between revisions

The OspC-based vaccine is currently a target to elicit protection against Lyme disease. Because of the polymorphism of OspC, the recombinant OspC vaccine, targeting the antigenic site of specific OspC type is ineffective for ''B. burgdorferi'' with different OspC types. Therefore, the development of vaccine that recognizes the antigenic determinant on the variable regions of multiple OspC types is required in order to effectively activate human immune response. Based on the mapping of epitope-containing regions from oMGs: A, B, K and D, the experiment-based tetravalent chimeric vaccine is developed to tigger anti-ABKD response. Then, taking advantage of tetravalent ABKD construct, octavalent chimeric vaccine also known as OspC-A8.1, recognizing the epitopes of oMGs: C, E, N and K, is  experimented in mice by using western blotting and ELISA. The construct of tetravalent and octavalent OspC vaccine are the underlying development of producing multiple OspC types vaccine to prevent the prevalence and risk of human Lyme disease.